Literature DB >> 9470130

The Lewy body variant of Alzheimer disease.

L A Hansen1.   

Abstract

The Lewy body variant of Alzheimer disease (LBV) occupies a messy middle ground between Alzheimer disease (AD) on the one hand, and pure Lewy body diseases (Parkinson's disease or diffuse Lewy body disease), on the other. In addition to brainstem and neocortical Lewy bodies, LBV brains have enough neocortical neuritic plaques to meet diagnostic criteria for AD. However, neurofibrillary pathology in LBV is modest, since tangle densities in LBV are typically intermediate between AD and age-matched controls or pure Lewy body disease brains. Apolipoprotein E-4 is overrepresented in LBV, as it is in AD but is not in PD or diffuse Lewy body disease (DLBD). Neurologically, LBV patients often display sufficient parkinsonian signs to separate them from AD, but these findings are usually too subtle to warrant clinical diagnoses of Parkinson's disease (PD). Neuropsychological deficits in LBV include a subcortical dementia pattern similar to DLBD, and more severe global cognitive impairment reminiscent of AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9470130     DOI: 10.1007/978-3-7091-6846-2_7

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  13 in total

1.  Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Authors:  Richard A Maki; Michael Holzer; Khatereh Motamedchaboki; Ernst Malle; Eliezer Masliah; Gunther Marsche; Wanda F Reynolds
Journal:  Free Radic Biol Med       Date:  2019-06-06       Impact factor: 7.376

2.  Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimer's Disease.

Authors:  Alan López-López; Ellen Gelpi; Diana Maria Lopategui; Jose M Vidal-Taboada
Journal:  Mol Neurobiol       Date:  2017-03-25       Impact factor: 5.590

3.  Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-04-29       Impact factor: 3.575

4.  A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression.

Authors:  Michael W Lutz; Robert Saul; Colton Linnertz; Omolara-Chinue Glenn; Allen D Roses; Ornit Chiba-Falek
Journal:  Alzheimers Dement       Date:  2015-06-13       Impact factor: 21.566

5.  The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease.

Authors:  Micaela Mitolo; David P Salmon; Simona Gardini; Douglas Galasko; Enzo Grossi; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.

Authors:  Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

7.  Limbic lobe microvacuolation is minimal in Alzheimer's disease in the absence of concurrent Lewy body disease.

Authors:  Yasuhiro Fujino; Dennis W Dickson
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

8.  α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease.

Authors:  Brian Spencer; Changyoun Kim; Tania Gonzalez; Alejandro Bisquertt; Christina Patrick; Edward Rockenstein; Anthony Adame; Seung-Jae Lee; Paula Desplats; Eliezer Masliah
Journal:  Hum Mol Genet       Date:  2016-01-05       Impact factor: 6.150

9.  Cerebral amyloid angiopathy in Lewy body disease.

Authors:  K A Jellinger; J Attems
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

10.  Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.

Authors:  Edward Rockenstein; Silke Nuber; Cassia R Overk; Kiren Ubhi; Michael Mante; Christina Patrick; Anthony Adame; Margarita Trejo-Morales; Juan Gerez; Paola Picotti; Poul H Jensen; Silvia Campioni; Roland Riek; Jürgen Winkler; Fred H Gage; Beate Winner; Eliezer Masliah
Journal:  Brain       Date:  2014-03-24       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.